TTNP Titan Pharmaceuticals Inc.

0.27
0  1%
Previous Close 0.27
Open 0.26
Price To Book 3.87
Market Cap 21106099
Shares 77,974,644
Volume 1,693,818
Short Ratio
Av. Daily Volume 12,282,724

SEC filingsSee all SEC filings

  1. PRE 14A - Other preliminary proxy statements 181218621
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181183539
  3. 8-K - Current report 181132892
  4. 8-K - Current report 181105670
  5. 8-K - Current report 181086289

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 treatment has commenced - noted October 11, 2017. DSMB recommended trial to continue - July 2, 2018 but further enrollment has been postponed due to lack of resources.
Ropinirole implant
Parkinson's disease
CRL issued April 30, 2013. Approved May 26 2016
Probuphine
Opioid dependence

Latest News

  1. Edited Transcript of TTNP earnings conference call or presentation 14-Nov-18 9:15pm GMT
  2. Alternatives to Watch
  3. Factors of Influence in 2018, Key Indicators and Opportunity within Atlantic American, Titan Medical, Adial Pharmaceuticals, Aptinyx, Sotherly Hotels, and Titan Pharmaceuticals — New Research Emphasizes Economic Growth
  4. TTNP: New CCO Implementing Targeted Strategy
  5. Titan Pharmaceuticals: 3Q Earnings Snapshot
  6. Titan Pharmaceuticals Reports Third Quarter 2018 Financial Results
  7. Titan Pharmaceuticals Schedules Conference Call To Review Third Quarter 2018 Financial Results
  8. Biotech Stocks and the Midterm Elections
  9. 3 Stocks To Watch As Healthcare Market Evolves
  10. Today’s Research Reports on Stocks to Watch: Conatus Pharmaceuticals and Titan Pharmaceuticals
  11. Surge In Healthcare Growth Sees Rally In These 3 Stocks On Friday
  12. 3 Healthcare Stocks that Could Move on Industry Growth
  13. Knight Therapeutics Announces the Canadian launch of PROBUPHINE™ for Opioid Use Disorder
  14. These 3 Stocks Are Moving Higher This Month
  15. Today's Research Reports on Trending Tickers: Titan Pharmaceuticals and Amarin Corporation
  16. Titan Pharmaceuticals Moving Forward with its ProNeura™ Technology, Analysts Review
  17. Titan Strengthens Executive Leadership Team With Appointment Of Chief Commercial Officer
  18. Titan Pharmaceuticals Prices $9,500,000 Public Offering
  19. Who Owns Titan Pharmaceuticals Inc (NASDAQ:TTNP)?
  20. Titan Awarded NIDA Grant For The Development Of A Nalmefene Implant For The Prevention Of Opioid Addiction Relapse

SEC Filings

  1. PRE 14A - Other preliminary proxy statements 181218621
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181183539
  3. 8-K - Current report 181132892
  4. 8-K - Current report 181105670
  5. 8-K - Current report 181086289
  6. 424B3 - Prospectus [Rule 424(b)(3)] 181084607
  7. 424B5 - Prospectus [Rule 424(b)(5)] 181082323
  8. EFFECT - Notice of Effectiveness 181080477
  9. S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933 181078802
  10. 8-K - Current report 181078632